accountWASHINGTON -(Dow Jones)- Federal regulators have sent a letter to Abbott Laboratories (ABT) warning the company that promotional material for the anti- epilepsy drug Depakote is misleading because it omits important risk information. Flashcards for...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to FDA: Abbott Promotional Material For Depakote Is Misleading
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account